Chang Gung Memorial Hospital

Cellular Therapy Emerges as a Front-Runner in Medical Innovation TAOYUAN, Oct. 20, 2024 /PRNewswire/ -- Cellular therapy, a revolutionary approach where cells are manipulated outside the body and then reintroduced to treat or prevent diseases, has been recognized in recent years as a highly promising treatment in the medical field. Chang Gung Memorial Hospital in Taiwan has been at the forefront of this innovation since 2018, when it established a Good Tissue Practice (GTP) laboratory with six cell processing labs adhering to international PICS/GMP cleanliness standards. The hospital actively supports clinical trials for various immune cells and regenerative medicine, with its Department of Laboratory Medicine certified by the College of American Pathologists (CAP) and responsible for issuing quality control reports for cell production processes. Continue Reading Chang Gung Memorial Hospital utilizes synthetic cancer cell antigens to train patients' immune cells to recognize and fight cancer cells. After multiplying, these immune cells are reintroduced into the body to eliminate cancer cells, all while using chemotherapy and radiotherapy to improve treatment outcomes. (Photo courtesy of Chang Gung Memorial Hospital) Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy (DC-CIK) Dr. Wei-Chen Lee, Vice-Superintendent at Chang Gung Memorial Hospital, Linkou, a leading institution in liver transplantation in Taiwan, has been researching autologous dendritic cells (DC) for liver cancer treatment since 1998. His therapy has achieved remarkable results, with no tumor growth post-treatment and a disease control rate of 70-80%. His team is now advancing research on cancer vaccines, aiming to initiate treatment immediately post-surgery to prevent cancer recurrence. Professor John Yu from the Institute of Stem Cell and Translational Cancer Research (ISCTCR) has developed a novel three-stage "apexNK" expansion technology for natural killer (NK) cells. Combined with a high-efficiency viral transduction method, this technology produces new CAR-NK cells, overcoming the limitations of traditional CAR therapies in treating solid tumors. Director Shuen-Iu Hung from the Cancer Vaccine and Immune Cell Therapy Core Laboratory has completed Phase I clinical trials targeting tumor neoantigens for solid cancer treatment, paving the way for future applications in metastatic and multidrug-resistant tumors. CAR-T Cell Therapy: A Living Drug Revolutionizing Cancer Treatment CAR-T cell therapy, or chimeric antigen receptor T-cell therapy, represents a groundbreaking immunotherapy that combines gene therapy and cellular therapy. Dubbed the "living drug," the treatment modifies the patient's immune T-cells genetically, enabling them to precisely target and eliminate specific cancer cells. These engineered and expanded T-cells are then reintroduced into the patient's body. The therapy has demonstrated remarkable success in treating acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), earning accelerated approval from the U.S. Food and Drug Administration (FDA). Huahua, a 13-year-old, and Baobao, an 8-year-old, both boys, serve as examples. Both were diagnosed with ALL and later developed extramedullary relapse, with Huahua experiencing bilateral testicular enlargement and Baobao showing enlargement of the right testicle, accompanied by an increase in minimal residual disease (MRD). Faced with these challenging cases, Dr. Shih-Hsiang Chen, Deputy Director of the hospital's Pediatric Department, noted the limited effectiveness of traditional hematopoietic stem cell transplantation for extramedullary relapse. Local treatments such as orchidectomy or radiotherapy could also significantly impact the reproductive function of pediatric patients. After thorough discussions with the patients' families, the decision was made to proceed with CAR-T cell therapy. Following treatment, both patients experienced only mild fever and fatigue and were discharged after approximately two weeks. They continue to receive outpatient follow-up care. Dr. Cheng-Hsun Chiu, also a Vice-Superintendent at the hospital, said that advancements in cancer treatment have transformed the landscape, evolving from traditional radiotherapy and chemotherapy to targeted therapy, bone marrow transplantation, and now, pioneering cellular therapies like DC-CIK and CAR-T. Looking ahead, the evolution of immune cell therapy promises to usher in more technological breakthroughs, offering patients a broader array of treatment choices and significantly enhancing both treatment efficacy and quality of life. SOURCE Chang Gung Memorial Hospital, Linkou WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Linkou Chang Gung Memorial Hospital and First Affiliated Hospital of Dalian Medical University use Vuzix M400 smart glasses during live surgeries ROCHESTER, N.Y., July 1, 2024 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of smart glasses and Augmented Reality (AR) technology and products, is pleased to announce that two of the most well-known hospitals in Asia, the Linkou Chang Gung Memorial Hospital and First Affiliated Hospital of Dalian Medical University, recently hosted live broadcasts of surgeries using Vuzix M400™ smart glasses. A live broadcast of knee joint surgery performed at the Linkou Chang Gung Memorial Hospital A replay of the cardiac surgery performed at the First Affiliated Hospital of Dalian Medical University can be viewed at

Trend Micro is showcasing new cybersecurity tools that run on Nvidia's chips at the Computex conference this week, according to Reuters. WHY IT MATTERS Healthcare organizations are using AI to ease documentation burdens across groups and may pull data from across their networks – including electronic health records – into one place hackers may target in their efforts to breach and ransom and sell healthcare data. "They work their way into the enterprise and they find this massive honeypot of information," Kevin Simzer, Trend Micro chief operating officer told Reuters. Simzer also told the wire service Sunday in Taiwan that the tools could also be used to protect data fed into AI systems, including generative AI chatbots that may contain protected information. Nvidia AI computing is being leveraged to enhance patient risk assessments, for example. National Health Research Institute and Chang Gung Memorial Hospital in Taiwan are using AI to predict the risk of chronic diseases by analyzing various genetic and environmental parameters according to the company. "This level of analysis was previously unattainable due to computational constraints," Dr. Hung-Yi Chiou, director of the Institute of Population Health Sciences at NHRI said in the Nvidia's blog post Sunday. THE LARGER TREND Many technology platforms healthcare organizations use now have AI integrations that tap into provider data, and many more will be cropping up in mobile applications accessed by providers and patients. Last year, Salesforce announced data cloud automation and AI integrations that create real-time patient profiles from EHR data and other systems. Many vendors offer similar chatbot-based access to streamline operations. Amanda Bury, chief commercial officer at Infermedica, a digital health company specializing in AI-powered systems for symptom analysis and patient triage, told Healthcare IT News last month that AI could optimize the patient portal and mobile experiences . "By integrating AI tools into familiar patient-facing technologies, such as patient portals or mobile applications, healthcare organizations can help guide patients toward the most appropriate care options, including telemedicine, based on their specific health profile, medical history and current symptoms," Bury said. While genAI may help better serve patient needs, hackers that phish or break their way into these systems can ask specific questions to get the underlying data. ON THE RECORD "That's what we're going to be looking for and making sure that we see it first and we can make sure that it doesn't go any further," Simzer told Reuters. Andrea Fox is senior editor of Healthcare IT News. Email: afox@himss.org Healthcare IT News is a HIMSS Media publication.